For colorectal cancer, targeted drugs do not treat as much as lung cancer. Therefore, for most colorectal patients, if there is a mutation in the KRAS gene or BRAF gene, the anti-angiogenic target drug bevacizumab is used in combination with chemotherapy, and if the above genes are not mutated, the EGFR antibody drug cetuximab is used in combination with chemotherapy. If the disease progresses, most colorectal cancer patients choose to participate in a clinical trial. Of course, we are also grateful to the scientists who developed the new drug, which not just reported a new treatment for bowel cancer at the ASCO congress, which doubled the overall overall survival in terms of treatment effect.
The picture comes from Photo.com
1. Novel therapeutic combination of EZFB
This newly reported study is not a single drug, but a combination of several drugs, including the dual A2a/A2b adenosine receptor antagonist etrumadenant (E), the immune checkpoint inhibitor zimberelimab (Z), and a chemotherapy regimen (FB: mFOLFOX-6± bevacizumab). It mainly depends on whether it can improve the survival of patients who have progressed after receiving clinical standard therapy.
The study enrolled 112 patients with metastatic colorectal cancer who had previously been treated with oxaliplatin and irinotecan in a phase Ib/II clinical trial and were randomized into two groups. Of these, 75 were treated with EZFB combinations and 37 were treated with regorafenib, a targeted drug alone.
Relevant data from clinical studies
Researchers at the UCLA Health Johnson Comprehensive Cancer Center reported the results at the American Clinical Oncology Annual Meeting on June 2, 2024. As shown in the figure above, the median follow-up was 20.4 months, in which the EZFB regimen had therapeutic advantages in both progression-free survival PFS and overall survival OS, which was significantly superior to the targeted regorafenib. Median progression-free survival was 6.2 months for the EZFB regimen and 2.1 months for regorafenib. The median overall survival was 19.7 months for the EZFB regimen compared to 9.5 months for regorafenib alone. That is, the combination of drugs can significantly improve the overall survival and progression-free survival of advanced colorectal cancer.
The results of the study also showed that 17.3% of patients received partial or complete tumor shrinkage after receiving the new combination therapy, that is, the treatment response rate determined by the EZFB drug regimen was 17.3%, while the treatment response rate of regorafenib in the control group was 2.7%, which is a huge gap.
Image source: Photo.com
2. Inspiration for us
If you look at the treatment response rate and survival data of regorafenib, you may understand the current situation faced by patients with advanced bowel cancer. When bowel cancer spreads to other parts of the body, treatment is more challenging, often requiring a combination of therapies, including surgery, chemotherapy, targeted therapy, and immunotherapy. Although these treatments have some effect, as later patients become resistant to various treatments and often end up with a situation where no drugs are available in clinical practice, new treatments need to be developed.
EZFB is a combination of drugs to enhance the therapeutic effect of chemotherapy and immunotherapy, in fact, in the later stage of treatment, the tumors in the patient's body are often very heterogeneous, and it is difficult to obtain good results with a single drug or a treatment regimen. I believe that there will be similar treatment options in China soon to carry out clinical trials, you can download the cancer app or pay attention to the cancer WeChat public account to sign up, in order to use this new treatment measures and programs as soon as possible, which will be of great help to everyone.
The "Genetic Testing, Accessible to Everyone" public welfare program launched by Cancerology and Geinga has a minimum of 3,000 yuan to detect 50 genes of tumor targeted drugs, escorting targeted therapy for patients! Welcome to private message cancer consultation.
Bibliography:
Abstract: meetings.asco.org/abstracts presentations/ 231642